09:48 AM EDT, 03/16/2026 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Monday that it has agreed to sell its serdexmethylphenidate, or SDX, portfolio that includes Azstarys and KP1077 to Commave Therapeutics for $50 million.

Before entering the sale agreement, Zevra Therapeutics ( ZVRA ) repaid the principal balance of its $63 million term loan in full, the company said.

Shares of the company were up 4.4% in Monday trading.

Price: 10.58, Change: +0.59, Percent Change: +5.96